ArticleInfection and drug resistance2024
The Distribution of Carbapenem-Resistant Acinetobacter Species and High Prevalence of CC92 OXA-23-Producing
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Detection ofMicrobiologyOpen · 2026Article
- Trends in Healthcare-Associated Infections Prevalence and Risk Factors: Repeated Point Prevalence Survey in a Milan Tertiary Hospital (2022-2025).Antibiotics (Basel, Switzerland) · 2026Article
- Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.BMC infectious diseases · 2026Article
- Clonal Dynamics and Antimicrobial Resistance of Bloodstream Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Comprehensive in silico analysis of Acinetobacter isolates from South Korea reveals genomic diversity, antimicrobial resistance, virulence factors, and evolutionary dynamics.Genes & genomics · 2026Article
- Genomic analysis of carbapenem-resistant non-Frontiers in microbiology · 2026Article
- Genomic Analysis of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical isolates of Materials and Methods: A total of 817 non-duplicated Results: A total of 659 Conclusion: Our results showed the distribution of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.